GPP
LKFT

Great Point Partners’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Great Point Partners’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-306,411
Closed -$13.1M – 46
2022
Q3 		$13.1M Sell
306,411
-53,589
-15% -$2.75M 3.15% 12
2022
Q2 		$20.1M Hold
360,000
– – 4.82% 7
2022
Q1 		$22.3M Buy
360,000
+60,000
+20% +$3.67M 5.4% 8
2021
Q4 		$16.5M Buy
+300,000
New +$15.7M 3.67% 8

Other funds holding LKFT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $2.8B AUM 13.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

Great Point Partners's LKFT Position: Q4 2022 in Review

Great Point Partners sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q4 2022, closing a stake of 306,411 shares — an estimated $13.1M sold.

Great Point Partners first reported a position in LKFT in Q4 2021 and held it in 4 quarters. The position peaked at $22.3M in Q1 2022. 74 funds tracked by Wall St. Rank hold LKFT as of Q4 2022.

  • Great Point Partners reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q4 2022 after selling out during the quarter.
  • Great Point Partners sold 306,411 Lakefront Biotherapeutics American Depositary Shares shares in Q4 2022, an estimated $13.1M.
  • Great Point Partners first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q4 2021 and held it in 4 quarters.
  • Great Point Partners's Lakefront Biotherapeutics American Depositary Shares position peaked at $22.3M in Q1 2022.
  • 74 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q4 2022.

Based on Great Point Partners's 13F filing for Q4 2022, filed 14 Feb 2023.